Ultomiris (ravulizumab) continues to be well tolerated and to keep symptoms of generalized myasthenia gravis (gMG) under control…
Margarida Maia, PhD
Science Writer
Margarida Maia, PhD, is a science and medical writer with a background in biochemistry and biomedical sciences. She studied in Portugal and Belgium and has been working in science communication for several years. She has been writing at Bionews since 2021. Her work focuses on explaining new research and medical developments on rare diseases in a clear and accessible way.
Education
- PhD in Biomedical Sciences, VIB & KU Leuven, Belgium
- Degree in Biochemistry, University of Porto, Portugal
Certifications
- Google Project Management: Professional Certificate
Published Works
- Valdez, Y, Maia, M, Conway EM. CD248: Reviewing its role in health and disease. Curr Drug Targets. 2012;13:432–439.
- Maia, M et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer. 2011;11:162.
- Antunes, R, Brandão, C, Maia, M, Arosa, FA. Red blood cells release factors with growth and survival bioactivities for normal and leukemic T cells. Immunol Cell Biol. 2011;89:111–121.
- Maia, M et al. CD248 and its cytoplasmic domain: A therapeutic target for arthritis. Arthritis Rheum. 2010;62:.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
NMD Pharma has been cleared by the U.S. Food and Drug Administration (FDA) to start a Phase 2b clinical…
Enspryng (satralizumab), which Chugai Pharmaceutical is testing for generalized myasthenia gravis (gMG), showed a significant benefit in…
Higher levels of an immune protein called macrophage migration inhibitory factor (MIF) in the blood are linked to more severe…
Periocular (around-the-eyeball) injections of triamcinolone, a corticosteroid, may ease early symptoms of ocular myasthenia gravis (MG) and reduce the…
TOL2, a medication being developed by Toleranzia for the treatment of myasthenia gravis (MG), was found to be…
In 2023, Myasthenia Gravis News brought up-to-date coverage of the latest scientific research and developments in the treatment of…
Vyvgart (efgartigimod alfa) has been listed on China’s 2023 National Reimbursement Drug List (NRDL) as a treatment for adults…
Treatment with intravenous immunoglobulin (IVIG) during pregnancy may have helped ease symptoms of a fetal disorder in a girl…
The experimental treatment povetacicept (ALPN-303) may be more effective than current available treatments for myasthenia gravis (MG), according to…